Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report
Introduction: Tepotinib is a targeted agent for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). Whereas durvalumab is an immune-checkpoint inhibitor (ICI), which has been administered to those with unresectable stage III...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000543251 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|